<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Factor IX, recombinant human: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Factor IX, recombinant human: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Factor IX, recombinant human: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="88573" href="/d/html/88573.html" rel="external">see "Factor IX, recombinant human: Drug information"</a> and <a class="drug drug_patient" data-topicid="88614" href="/d/html/88614.html" rel="external">see "Factor IX, recombinant human: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F16255881"><span class="drugH1">Brand Names: US</span>
<ul>
<li>BeneFIX;</li>
<li>Ixinity;</li>
<li>Rixubis</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865422"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>BeneFIX;</li>
<li>Rixubis</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F989980"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antihemophilic Agent</span></li></ul></div>
<div class="block don drugH1Div" id="F53462630"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d3c8dbc-ec3d-4b92-8b0e-9f550b04753f">Hemophilia B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B (Christmas disease):</b> Individualize dosage based on clinical response and factor IX activity evaluated at baseline and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for control or prevention of bleeding episodes or perioperative management:</b> IV: <b>Note:</b> Dosage is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleed, individualized incremental recovery using factor IX activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Formula for units required to raise blood level: </i></p>
<p style="text-indent:-2em;margin-left:8em;">BeneFIX:</p>
<p style="text-indent:-2em;margin-left:10em;">Number of Factor IX Units Required = body weight (in kg) x desired factor IX level increase (% or units/dL) x 1.4 units/kg per units/dL</p>
<p style="text-indent:-2em;margin-left:12em;">For example, for a 100% level in a 3 kg patient who has an actual level of 20%: Number of Factor IX Units needed = 3 kg x 80% x 1.4 units/kg per units/dL = 336 units</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Treatment recommendations (WFH [Srivastava 2020]):</i>
<b>Note:</b> Ages vary by product; see product-specific labeling for approved ages. Factor IX level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:8em;">Intermittent IV: The following recommendations reflect WFH guidelines for higher dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. If factor IX levels are available, subsequent doses should be based on the half-life of factor IX and on the recovery in an individual patient for a particular product.</p>
<table border="1" frame="border" rules="all" style="margin-left:6em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor IX Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>A</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A</sup>Frequency is based on type of bleed or surgery and varies by product; frequency in chart based on BeneFIX; if using different product see specific product labeling for details.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 60% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 20% to 40%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis: Note:</b> Maintain factor IX trough levels &gt;3% to 5% or higher as clinically indicated (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:6em;">BeneFIX: IV: 100 units/kg/dose once weekly; more frequent or higher doses may be required due to lower recovery, shorter half-life, and higher drug clearance; titrate dose or frequency based on patient's clinical response.</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F16257745"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9d3c8dbc-ec3d-4b92-8b0e-9f550b04753f">Hemophilia B</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B (Christmas disease):</b> Individualize dosage based on clinical response and factor IX activity evaluated at baseline and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>General dosing for</b>
<b>control or prevention of bleeding episodes or perioperative management:</b> IV: <b>Note: </b>Dosage is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleed, individualized incremental recovery using factor IX activity assays, and clinical situation of patient.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents (ages vary by product; see product-specific labeling for approved ages): IV:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Formula for units required to raise blood level: </i></p>
<p style="text-indent:-2em;margin-left:10em;">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x reciprocal of observed recovery (as units/kg per units/dL)</p>
<p style="text-indent:-2em;margin-left:10em;">Reciprocal of average observed recovery (as units/kg per units/dL):</p>
<p style="text-indent:-2em;margin-left:12em;">BeneFIX:</p>
<p style="text-indent:-2em;margin-left:14em;">Infants, Children, and Adolescents &lt;15 years: 1.4</p>
<p style="text-indent:-2em;margin-left:14em;">Adolescents ≥15 years: 1.3</p>
<p style="text-indent:-2em;margin-left:12em;">Ixinity: Children ≥12 years and Adolescents: 1.02</p>
<p style="text-indent:-2em;margin-left:12em;">Rixubis:</p>
<p style="text-indent:-2em;margin-left:14em;">Infants and Children &lt;12 years: 1.4</p>
<p style="text-indent:-2em;margin-left:14em;">Children ≥12 years and Adolescents: 1.1</p>
<p style="text-indent:-2em;margin-left:12em;">For example for BeneFIX, for a 100% level in a 25 kg patient &lt;15 years who has an actual level of 20%: Number of factor IX Units needed = 25 kg x 80% x 1.4 units/kg per units/dL = 2,800 units</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Treatment recommendations (WFH [Srivastava 2020]):</i>
<b>Note:</b> Ages vary by product; see product-specific labeling for approved ages. Factor IX level may either be expressed as % or as units/dL.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent IV: The following recommendations reflect WFH guideline recommendations for higher dose practice patterns; this dosing is typically used in areas where no significant resource constraints exist; recommendations may vary from those found within prescribing information or practitioner preference. Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details. If factor IX levels are available, subsequent doses should be based on the half-life of factor IX and on the recovery in an individual patient for a particular product.</p>
<table border="1" frame="border" rules="all" style="margin-left:8em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Site of Hemorrhage/Clinical Situation</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Desired Factor IX Peak Level</b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Frequency<sup>A</sup></b></p></th>
<th align="center">
<p style="text-indent:0em;">
<b>Duration</b></p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="4">
<p style="text-indent:0em;text-align:left;">
<sup>A</sup>Frequency is based on type of bleed or surgery and varies by product; see specific product labeling for details.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;">Joint</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">1 to 2 days, may be longer if response is inadequate</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Superficial muscle/no neurovascular compromise</p></td>
<td align="center">
<p style="text-indent:0em;">40% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3 days, sometimes longer if response is inadequate</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 2 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30% to 60%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">CNS/Head</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 21 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Throat and neck</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 1 to 7 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 8 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Gastrointestinal</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 60% to 80%</p></td>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Initial:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> 30%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Maintenance:</i> Not specified</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Renal</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">3 to 5 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">Deep laceration</p></td>
<td align="center">
<p style="text-indent:0em;">40%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 7 days</p></td></tr>
<tr>
<td align="center" rowspan="4">
<p style="text-indent:0em;">Surgery (major)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 60% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 40% to 60%</p></td>
<td align="center" rowspan="3">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 3 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 50%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 4 to 6 days</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 20% to 40%</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 7 to 14 days</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">Surgery (minor)</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Preop:</i> 50% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Single dose</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 30% to 80%</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">
<i>Postop:</i> 1 to 5 days depending on procedure type</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:10em;">Continuous IV infusion: Limited data available: Infants, Children, and Adolescents: <b>Note: </b>In general, administration of factor IX 7.5 units/kg/hour will increase circulating factor IX levels by 1 unit/mL (Prelog 2016).</p>
<p style="text-indent:-2em;margin-left:12em;">
<i>Control and prevention of bleeding episodes and perioperative management: </i>
<b>Note:</b> For patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusions (Batorova 2002; Morfini 2008; Poon 2012; Prelog 2016; WFH [Srivastava 2020]). Evidence supporting the use of continuous infusion is primarily with BeneFIX (Chowdary 2001); however, manufacturer's labeling states that safety and efficacy of BeneFIX administration by continuous infusion has not been established.</p>
<p style="text-indent:-2em;margin-left:12em;">Following initial bolus to achieve the desired factor IX level (Poon 2012): Initial dosing: 4 to 6 units/kg/hour; adjust dose based on frequent factor IX assays and calculation of factor IX clearance at steady-state using the following equations:</p>
<p style="text-indent:-2em;margin-left:14em;">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) / (plasma Factor IX level in units/<b>mL</b>)</p>
<p style="text-indent:-2em;margin-left:14em;">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/<b>mL</b>)</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Routine prophylaxis:</b>
<b>Note: </b>Adjust dose based on clinical response.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Product-specific dosing:</i></p>
<p style="text-indent:-2em;margin-left:8em;">BeneFIX:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants, Children, and Adolescents: IV: 100 units/kg/dose once weekly; titrate dose or frequency based on patient's clinical response. <b>Note: </b>For pediatric patients &lt;12 years of age, more frequent or higher doses may be required due to lower recovery, shorter half-life, and higher drug clearance.</p>
<p style="text-indent:-2em;margin-left:8em;">Ixinity: Children ≥12 years and Adolescents: IV: 40 to 70 units/kg/dose twice weekly; titrate dose depending upon age, bleeding pattern, and physical activity.</p>
<p style="text-indent:-2em;margin-left:8em;">Rixubis:</p>
<p style="text-indent:-2em;margin-left:10em;">Infants and Children &lt;12 years: IV: 60 to 80 international units/kg/dose 2 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Children ≥12 years and Adolescents: IV: 40 to 60 international units/kg/dose 2 times weekly.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Guideline dosing (WFH [Srivastava 2020]):</i>
<b>Note: </b>Maintain factor IX trough levels &gt;3% to 5% or higher as clinically indicated. Dose should be individualized; dose intensity should take into account disease severity, patient's activity and lifestyle, and pharmacokinetic properties of product and should be adjusted if breakthrough bleeding occurs. See guidelines for in-depth discussion of risks and benefits of each dosing approach.</p>
<p style="text-indent:-2em;margin-left:8em;">Infants, Children, and Adolescents: IV:</p>
<p style="text-indent:-2em;margin-left:10em;">High dose: 40 to 60 units/kg/dose 2 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Intermediate dose: 20 to 40 units/kg/dose 2 times weekly.</p>
<p style="text-indent:-2em;margin-left:10em;">Low dose: 10 to 15 units/kg/dose 2 times weekly. <b>Note: </b>Low dose prophylaxis may be used in young patients as initial therapy; close monitoring is required since patients are at a higher risk for bleeding until escalation occurs.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109872"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels.</p></div>
<div class="block dohp drugH1Div" id="F51109873"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>
<div class="block doa drugH1Div" id="F16257752"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="88573" href="/d/html/88573.html" rel="external">see "Factor IX, recombinant human: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="98495059-e110-44f0-ad91-ba0bd4d84e5d">Hemophilia B, without inhibitors</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemophilia B, without inhibitors:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>Contains <b>only factor IX</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of other clotting factors besides factor IX, hemophilia A patients with inhibitors to factor VIII, reversal of anticoagulation due to vitamin K antagonists or other anticoagulants, or bleeding due to low levels of liver-dependent clotting factors.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Treatment and control of bleeding episodes or perioperative management:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>
<i>Intermittent IV bolus dosing:</i> IV: </b>Utilize steps 1 to 4 to determine intermittent bolus dosing strategy. Individualize dosage based on coagulation studies performed prior to treatment and at regular intervals during treatment.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 1:</b> Identify product-specific in vivo recovery (IVR) for dosing calculations (<b>Note:</b> IVR indicates the expected increase in factor IX level, which occurs with 1 unit/kg of factor IX product administration):</p>
<p style="text-indent:-2em;margin-left:8em;">BeneFIX IVR: 0.76.</p>
<p style="text-indent:-2em;margin-left:8em;">Ixinity IVR: 0.98.</p>
<p style="text-indent:-2em;margin-left:8em;">Rixubis IVR: 0.9.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 2:</b> Determine desired factor IX peak level and anticipated duration of therapy based on the World Federation of Hemophilia (WFH) treatment recommendations; see table. Selection of the lower-dose practice pattern requires closer observation with the potential for requiring escalation to higher doses based on clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Factor IX (Recombinant) WFH Treatment Recommendations<sup>a</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Type of hemorrhage or surgery</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Lower dose practice pattern</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;text-align:left;">Higher dose practice pattern</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treatment duration (days)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Desired peak factor IX level (units/dL)</p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">Treatment duration (days)</p></th></tr></thead>
<tfoot>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<sup>a </sup>WFH = World Federation of Hemophilia (WFH [Srivastava 2020]).</p>
<p style="text-indent:0em;text-align:left;">
<sup>b </sup>May be longer if response is inadequate.</p>
<p style="text-indent:0em;text-align:left;">
<sup>c</sup> A single dose may be sufficient for some joint bleeds; determine need for additional doses based on clinical response.</p>
<p style="text-indent:0em;text-align:left;">
<sup>d </sup>Sometimes longer as secondary prophylaxis during physical therapy.</p></td></tr></tfoot>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Joint</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,c</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2<sup>b,c</sup></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Superficial muscle/no neurovascular compromise (except iliopsoas)</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">2 to 3<sup>b</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Iliopsoas or deep muscle with neurovascular injury or substantial blood loss</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 2</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>d</sup></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5<sup>d</sup></p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Intracranial</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 21</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Throat and neck</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 7</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>GI</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Initial</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Maintenance</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Renal</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">3 to 5</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">
<b>Deep laceration</b></p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">15 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">5 to 7</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (major)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 70</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">60 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">-</p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 60</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 3</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 30</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">4 to 6</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">10 to 20</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 40</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">7 to 14</p></td></tr>
<tr>
<td align="center" colspan="5">
<p style="text-indent:0em;text-align:left;">
<b>Surgery (minor)</b></p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Pre-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">40 to 80</p></td>
<td align="center"></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 to 80</p></td>
<td align="center"></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Post-op</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">20 to 50</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">30 to 80</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1 to 5</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 3:</b> Calculate dose using IVR from step 1, desired peak factor IX level from step 2, and the following equation:</p>
<p style="text-indent:-2em;margin-left:8em;">Factor IX units required = [(desired peak factor IX level − patient's baseline factor IX level) × body weight (kg)]/IVR</p>
<p style="text-indent:-2em;margin-left:10em;">(<b>Note:</b> Factor IX units are in units/dL.)</p>
<p style="text-indent:-2em;margin-left:8em;">Example (BeneFIX) for 50 kg patient with desired peak factor IX level of 35 units/dL, baseline factor IX level of 5 units/dL, IVR = 0.76:</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX units required = [(35 units/dL − 5 units/dL) × 50 kg)] ⁄ 0.76 = 1,974 units factor IX</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Step 4:</b> Determine need for repeat dosing based on manufacturer’s recommended frequency of repeat dosing.<b> Note:</b> Frequency of administration must also take into consideration subsequent factor IX activity measurements and clinical response.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption>
<b>Factor IX (Recombinant) Administration Frequency According to Clinical Scenario</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Product</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Bleeding event</p></th>
<th align="center" colspan="2">
<p style="text-indent:0em;">Surgery</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Minor severity</p></th>
<th align="center">
<p style="text-indent:0em;">Moderate severity</p></th>
<th align="center">
<p style="text-indent:0em;">Major severity</p></th>
<th align="center">
<p style="text-indent:0em;">Minor bleeding risk</p></th>
<th align="center">
<p style="text-indent:0em;">Major bleeding risk</p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">BeneFIX</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Ixinity</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Every 8 to 24 hours</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">Rixubis</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 12 to 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 24 hours</p></td>
<td align="center">
<p style="text-indent:0em;">Every 8 to 24 hours</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:6em;">
<i>
<b>Continuous infusion administration </b></i>(Batorova 2002; Batorova 2012; Chowdary 2001; Holme 2018; Poon 2012; Ragni 2002; Rickard 1995; WFH [Srivastava 2020]):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Continuous infusion administration is preferred over intermittent bolus administration for patients requiring prolonged treatment courses (eg, postoperative management after surgery with major bleeding risk). To ensure safe and effective use, only products with extended stability information should be used. Extended stability information may not be available for all products; contact product manufacturer to obtain current recommendations. Use of a smart infusion pump with small volume infusion capability is also necessary.</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV: </b>Administer an initial bolus to achieve the desired factor IX level (see steps 1 to 3 under "Intermittent bolus dosing"), then initiate continuous infusion of 4 to 6 units/kg/hour. Adjust dose based on frequent factor assays (at least daily) and calculation of factor IX clearance at steady state using the following equations.</p>
<p style="text-indent:-2em;margin-left:10em;">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour) divided by (measured factor IX level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) × (desired factor IX level in units/mL)</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> With infusion dose increases, re-bolus should be considered to achieve target factor IX level more quickly. See steps 1 to 3 under "Intermittent IV bolus dosing" to determine re-bolus dose.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with moderate/severe hemophilia B without inhibitors:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Dosing should be tailored to ensure trough factor IX levels of at least 1% and preferably ≥3% to 5% are achieved, but prophylaxis targets should be tailored to individual level of activity, lifestyle, and pharmacokinetics. Dose escalation should be considered for patients adherent to prescribed prophylaxis but still experiencing breakthrough bleeding events (WFH [Srivastava 2020])<i>.</i></p>
<p style="text-indent:-2em;margin-left:6em;">BeneFIX: <b>IV:</b> 100 units/kg once weekly; may titrate dose or frequency based on patient’s clinical response.</p>
<p style="text-indent:-2em;margin-left:6em;">Ixinity: <b>IV:</b> 40 to 70 units/kg twice weekly; may titrate dose based on patient’s age, bleeding pattern, and physical activity.</p>
<p style="text-indent:-2em;margin-left:6em;">Rixubis: <b>IV:</b> 40 to 60 units/kg twice weekly; may titrate dose depending upon age, bleeding pattern, and physical activity.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990461"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels.</p></div>
<div class="block doha drugH1Div" id="F50987694"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; monitor factor IX levels. Use with caution due to the risk of thromboembolic complications.</p></div>
<div class="block adr drugH1Div" id="F242345"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (2% to 30%; against factor IX, CHO proteins, and furin [indeterminate specificity]; may be neutralizing)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Headache (3% to 11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest tightness (2%), flushing (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritic rash (1%), skin rash (2% to 6%), urticaria (3% to 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysgeusia (1% to 5%), nausea (6%), vomiting (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Factor IX inhibitor in hemophilia B (2% to 3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Cellulitis at injection site (2%), discomfort at injection site (1%), injection site phlebitis (2%), injection site reaction (2% to 8%), pain at injection site (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Apathy (1%), chills (2%), depression (1%), dizziness (8%), drowsiness (2%), lethargy (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia (1%), limb pain (1%), tremor (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal infarction (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry cough (2%), dyspnea (3%), hypoxia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Deep vein thrombosis, hypotension, peripheral thrombophlebitis, superior vena cava syndrome (neonates), thrombosis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Nephrotic syndrome (associated with immune tolerance induction)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p></div>
<div class="block coi drugH1Div" id="F242351"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Life-threatening, immediate hypersensitivity reactions (including anaphylaxis) to coagulation factor IX, hamster protein, or any component of the formulation; disseminated intravascular coagulation (Rixubis); signs of fibrinolysis (Rixubis).</p></div>
<div class="block war drugH1Div" id="F242343"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis) may occur; risk is highest during the early phases of initial exposure in previously untreated patients, especially those with high-risk gene mutations. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions have frequently occurred in close temporal association with the development of factor IX inhibitors; patients experiencing allergic reactions should be evaluated for factor IX inhibitors. If hypersensitivity reactions occur, discontinue immediately; in the case of severe allergic reactions, consider the use of alternative hemostatic measures (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Nephrotic syndrome: Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions. Safety and efficacy in this situation have not been established.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thrombotic events: Thromboembolism (eg, pulmonary embolism, venous/arterial thrombosis) may occur. Monitor for early signs of thromboembolism and coagulopathy in patients with hepatic disease, fibrinolysis, peri- and postoperative patients, or patients at risk for thromboembolic events or disseminated intravascular coagulation (DIC). The benefit of treatment should be weighed against the risk of complications in patients with DIC or those at risk for DIC or thromboembolic events. Reports of thrombotic events have also been reported in patients receiving continuous infusion through a central venous catheter, including life-threatening superior vena cava syndrome in critically ill neonates.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the increased risk of thromboembolic complications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Hamster protein: May contain trace amounts of Chinese hamster proteins; hypersensitivity to these proteins may develop.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878685"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Use with caution when administering to neonates; the safety and efficacy of continuous infusion administration has not been established; thrombotic events have been reported in patients receiving continuous infusion of recombinant Factor IX through a central venous catheter, including life-threatening superior vena cava syndrome in neonates. </p></div>
<div class="block dosfc drugH1Div" id="F25573584"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>
<div class="block foc drugH1Div" id="F242348"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BeneFIX: 250 units, 500 units, 1000 units, 2000 units, 3000 units [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 250 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 250 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 500 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 500 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 1000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 1000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 1500 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 1500 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 2000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 2000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 3000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Ixinity: 3000 units (1 ea) [contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Rixubis: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F16255883"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F21663576"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Kit</b> (BeneFIX Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.04</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Ixinity Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 unit (Price provided is per AHF Unit): $2.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 unit (Price provided is per AHF Unit): $2.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 unit (Price provided is per AHF Unit): $2.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1500 unit (Price provided is per AHF Unit): $2.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2000 unit (Price provided is per AHF Unit): $2.38</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">3000 unit (Price provided is per AHF Unit): $2.38</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865423"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Kit, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">BeneFIX: 250 units [DSC], 500 units, 1000 units, 2000 units, 3000 units</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52614070"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Parenteral: IV administration only; use administration sets/tubing provided by manufacturer (if provided). Solution should be infused at room temperature. With patients who have had allergic reactions during factor IX infusion, administration of antihistamine prior to infusion may be necessary (WFH [Srivastava 2020]).</p>
<p style="text-indent:-2em;margin-left:2em;">Intermittent IV:</p>
<p style="text-indent:-2em;margin-left:4em;">BeneFIX: Should be infused <b>slowly over several minutes</b>. Rate of administration should be determined by the response and comfort of the patient.</p>
<p style="text-indent:-2em;margin-left:4em;">Ixinity: Rate of administration should be determined by the comfort of the patient; maximum rate of administration is 10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:4em;">Rixubis: Maximum rate of administration is 10 mL/minute.</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous IV infusion: Limited data available in select patients: Infuse as directed. Evidence supporting the use of continuous infusion is primarily with BeneFIX (Chowdary 2001); however, manufacturer's labeling states that safety and efficacy of BeneFIX and Rixubis administration by continuous infusion has not been established. Further dilution after initial reconstitution is unnecessary (Batorova 2002; Prelog 2016).</p></div>
<div class="block adm drugH1Div" id="F16257758"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Solution should be infused at room temperature. Safety and efficacy of continuous infusion administration have not been determined.</p>
<p style="text-indent:-2em;margin-left:2em;">IV administration only:</p>
<p style="text-indent:-2em;margin-left:4em;">Rixubis: For bolus infusion only; maximum rate of administration is 10 mL/minute</p>
<p style="text-indent:-2em;margin-left:4em;">BeneFIX: Should be infused <b>slowly over several minutes</b>. Rate of administration should be determined by the response and comfort of the patient. Do not administer as a continuous infusion.</p>
<p style="text-indent:-2em;margin-left:4em;">Ixinity: Rate of administration should be determined by the comfort of the patient; maximum rate of administration is 10 mL/minute</p>
<p style="text-indent:-2em;margin-left:2em;">Continuous infusion (off-label rate): Some products may be administered as a continuous infusion to avoid peaks and troughs associated with intermittent infusions in patients who require prolonged treatment periods. Use a smart infusion pump with small volume infusion capability. Refer to protocols for product selection and preparation details (Batorova 2002; Batorova 2012; Chowdary 2001; Holme 2018; Poon 2012; Ragni 2002; Rickard 1995; WFH [Srivastava 2020]).</p></div>
<div class="block sts drugH1Div" id="F16256024"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">BeneFIX: Store at 2°C to 30°C (36°F to 86°F). Avoid freezing which may damage the diluent syringe. Reconstituted solution should be at room temperature and used within 3 hours of preparation. Do not refrigerate after reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">Ixinity: Store 250 unit strength at 2°C to 8°C (36°F to 47°F); store 500 unit, 1,000 unit, 1,500 unit, 2,000 unit, and 3,000 unit strength at 2°C to 25°C (36°F to 77°F). Do not freeze. Keep vial in the carton and protect from light. Infuse reconstituted solution immediately or within 3 hours when stored at room temperature. Do not refrigerate after reconstitution.</p>
<p style="text-indent:-2em;margin-left:2em;">Rixubis: Store at 2°C to 8°C (36°F to 46°F); do not freeze. May store at room temperature not to exceed 30°C (86°F) for up to 36 months; do not return to refrigerator. Infuse  at room temperature and within 3 hours of reconstitution; do not refrigerate after reconstitution.</p></div>
<div class="block usep drugH1Div" id="F53569666"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">
<b>Note: </b>Products contains <b>only factor IX</b>. These products are <b>NOT INDICATED</b> for the treatment of other factor deficiencies (eg, factor II, VII, VIII, X), for the treatment of hemophilia A patients with inhibitors to factor VIII, the reversal of coumarin-induced anticoagulation, for the treatment of bleeding because of low levels of liver-dependent coagulation factors, or for induction of immune tolerance in patients with hemophilia B.</p>
<p style="text-indent:-2em;margin-left:2em;">Prevention and control of bleeding in patients with hemophilia B (congenital factor IX deficiency or Christmas disease) (BeneFIX, Rixubis: FDA approved in pediatric patents [age not specified] and adults; Ixinity: FDA approved in ages ≥12 years and adults); perioperative management in patients with hemophilia B (BeneFIX, Rixubis: FDA approved in pediatric patents [age not specified] and adults; Ixinity: FDA approved in ages ≥12 years and adults); routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (BeneFIX, Rixubis: FDA approved in pediatric patents [age not specified] and adults; Ixinity: FDA approved in ages ≥12 years and adults).</p></div>
<div class="block mst drugH1Div" id="F16255858"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Factor IX may be confused with Factor IX Complex</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F16369070"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F16369068"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block pri drugH1Div" id="F16255898"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Pregnant carriers of hemophilia B may have an increased bleeding risk following invasive procedures, spontaneous miscarriage, termination of pregnancy, and delivery; close surveillance is recommended. Factor IX levels should be monitored at the first antenatal visit, once or twice during the third trimester, prior to surgical or invasive procedures, and at delivery. Although factor IX levels remain stable during pregnancy, factor IX replacement is recommended if concentrations are &lt;50 units/dL and any of the following occur: need for invasive procedures (including delivery), spontaneous miscarriage, insertion and removal of epidural catheters, or active bleeding. Hemostatic factor IX concentrations should be maintained for at least 3 to 5 days following invasive procedures or postpartum. If replacement with a factor IX concentrate is indicated to increase factor IX during pregnancy, a recombinant product is preferred (NHF 2017; RCOG [Pavord 2017]; WFH [Srivastava 2020]).</p></div>
<div class="block mopp drugH1Div" id="F53569627"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Factor IX levels by the one-stage clotting assay (measure 15 to 30 minutes after infusion to verify calculated doses) (WFH [Srivastava 2020]), signs of hypersensitivity reactions, disseminated intravascular coagulation, and thrombosis. Screen for factor IX inhibitors if the patient experiences hypersensitivity reaction or when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days, or after recurrent bleeds despite adequate factor IX replacement; all patients should have factor IX inhibitors screened every 6 to 12 months after therapy is initiated and then annually (WFH [Srivastava 2020]).</p></div>
<div class="block rerp drugH1Div" id="F53569174"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">Classification of hemophilia (WFH [Srivastava 2020]):</p>
<p style="text-indent:-2em;margin-left:4em;">Severe: Factor level &lt;1% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate: Factor level 1% to 5% of normal.</p>
<p style="text-indent:-2em;margin-left:4em;">Mild: Factor level 5% to &lt;40% of normal.</p></div>
<div class="block pha drugH1Div" id="F16256038"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa) in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>
<div class="block phk drugH1Div" id="F242350"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>:</p>
<p style="text-indent:-2em;margin-left:4em;">BeneFIX: Children &lt;2 years of age: 252 ± 35 mL/kg; Children 2 to &lt;6 years of age: 257 ± 25 mL/kg; Children 6 to &lt;12 years of age: 303 mL/kg; Children ≥12 years of age, Adolescents, and Adults: 229 ± 57 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Ixinity: 102 to 314 mL/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Rixubis: Children &lt;6 years of age: ~0.3 L/kg; Children ≥6 years of age, Adolescents, and Adults: ~0.2 L/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">BeneFIX:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;2 years of age: Mean: 15.6 ± 1.2 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 2 to &lt;6 years of age: Mean: 16.7 ± 1.9 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to &lt;12 years of age: Mean: 16.3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years of age, Adolescents, and Adults: 23.1 ± 4.4 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Ixinity: Children ≥12 years of age, Adolescents, and Adults: Mean: 24 ± 7 hours; range: 13 to 43 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Rixubis:</p>
<p style="text-indent:-2em;margin-left:6em;">Children &lt;6 years of age: Mean: 27.7 ± 2.7 hours; range: 24 to 32.2 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to &lt;12 years of age: 25.3 ± 1.8 hours; range: 23.7 to 30.3 hours.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years of age, Adolescents, and Adults:</p>
<p style="text-indent:-2em;margin-left:8em;">Single dose: Mean: 26.7 ± 9.6 hours; range: 15.8 to 52.3 hours.</p>
<p style="text-indent:-2em;margin-left:8em;">Repeat dosing: Mean: 25.4 ± 6.9 hours; range: 16.2 to 42.2 hours.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F23672676"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Factor de coagulacion ix octapharma</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Agemfil b | Innonafactor</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Benefix</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12010406">
<a name="12010406"></a>Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177. doi:10.1046/j.1365-2516.2002.00635.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/12010406/pubmed" id="12010406" target="_blank">12010406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22530687">
<a name="22530687"></a>Batorova A, Holme P, Gringeri A, et al; European Haemophilia Treatment Standardisation Board. Continuous infusion in haemophilia: current practice in Europe. <i>Haemophilia</i>. 2012;18(5):753-759. doi:10.1111/j.1365-2516.2012.02810.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/22530687/pubmed" id="22530687" target="_blank">22530687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-BeneFIX.1">
<a name="BeneFIX.1"></a>BeneFIX (coagulation factor IX [recombinant]) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals LLC; November 2022.</div>
</li>
<li>
<div class="reference">
                  Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22101176">
<a name="22101176"></a>Chi C, Kadir RA. Inherited bleeding disorders in pregnancy. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2012;26(1):103-117.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/22101176/pubmed" id="22101176" target="_blank">22101176</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11260272">
<a name="11260272"></a>Chowdary P, Dasani H, Jones JAH, et al. Recombinant factor IX (BeneFix®) by adjusted continuous infusion: a study of stability, sterility and clinical experience. <i>Haemophilia</i>. 2001;7:140-145. doi:10.1046/j.1365-2516.2001.00494.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/11260272/pubmed" id="11260272" target="_blank">11260272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28873263">
<a name="28873263"></a>Holme PA, Tjønnfjord GE, Batorova A. Continuous infusion of coagulation factor concentrates during intensive treatment. <i>Haemophilia</i>. 2018;24(1):24-32. doi:10.1111/hae.13331<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/28873263/pubmed" id="28873263" target="_blank">28873263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ixinity.1">
<a name="Ixinity.1"></a>Ixinity (coagulation factor IX [recombinant]) [prescribing information]. Chicago, IL: Medexus Pharma Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19298378">
<a name="19298378"></a>Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/19298378/pubmed" id="19298378" target="_blank">19298378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16834731">
<a name="16834731"></a>Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a Taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/16834731/pubmed" id="16834731" target="_blank">16834731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19105506">
<a name="19105506"></a>Morfini M. Secondary prophylaxis with factor IX concentrates: continuous infusion. <i>Blood Transfus</i>. 2008;6(Suppl 2):21–25.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/19105506/pubmed" id="19105506" target="_blank">19105506</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  National Hemophilia Foundation (NHF). Medical and Scientific Advisory Council (MASAC) guidelines for perinatal management of women with bleeding disorders and carriers of hemophilia A and B (MASAC document 251). https://www.hemophilia.org/node/3660. Published September 17, 2017. Accessed June 7, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28447403">
<a name="28447403"></a>Pavord S, Rayment R, Madan B, et al; for the Royal College of Obstetricians and Gynaecologists. Management of inherited bleeding disorders in pregnancy: Green-top Guideline No. 71 (joint with UKHCDO). <i>BJOG</i>. 2017;124(8):e193–e263. doi:10.1111/1471-0528.14592<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/28447403/pubmed" id="28447403" target="_blank">28447403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22503305">
<a name="22503305"></a>Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307. doi:10.1016/j.transci.2012.03.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/22503305/pubmed" id="22503305" target="_blank">22503305</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26674820">
<a name="26674820"></a>Prelog T, Dolničar MB, Kitanovski L. Low-dose continuous infusion of factor VIII in patients with haemophilia A. <i>Blood Transfus</i>. 2016;14(5):474‐480.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/26674820/pubmed" id="26674820" target="_blank">26674820</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11952843">
<a name="11952843"></a>Ragni MV, Pasi KJ, White GC, Giangrande PL, Courter SG, Tubridy KL; Recombinant FIX Surgical study group. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. <i>Haemophilia</i>. 2002;8(2):91-97. doi:10.1046/j.1365-2516.2002.00587.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/11952843/pubmed" id="11952843" target="_blank">11952843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27214734">
<a name="27214734"></a>Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(suppl 1):8-13. doi:10.1111/j.1365-2516.1995.tb00104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/27214734/pubmed" id="27214734" target="_blank">27214734</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rixubis.1">
<a name="Rixubis.1"></a>Rixubis (coagulation factor IX [recombinant]) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals USA Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12694516">
<a name="12694516"></a>Shibata M, Shima M, Misu H, et al. Management of Haemophilia B Inhibitor Patients With Anaphylactic Reactions to FIX Concentrates. <i>Haemophilia</i>. 2003;9(3):269-271.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/12694516/pubmed" id="12694516" target="_blank">12694516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10938981">
<a name="10938981"></a>Shord SS, Lindley CM. Coagulation Products and Their Uses. <i>Am J Health Syst Pharm</i>. 2000;57(15):1403-1417.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/10938981/pubmed" id="10938981" target="_blank">10938981</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Srivastava A, Santagostino E, Dougall A, et al; WFH Guidelines for the Management of Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition. <i>Haemophilia</i>. 2020;26(suppl 6):1-158. doi:10.1111/hae.14046<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/32744769/pubmed" id="32744769" target="_blank">32744769</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9873771">
<a name="9873771"></a>Varon D, Martinowitz U. Continuous Infusion Therapy in Haemophilia. <i>Haemophilia</i>. 1998;4(4):431-435.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/9873771/pubmed" id="9873771" target="_blank">9873771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9198163">
<a name="9198163"></a>White GC 2nd, Beebe A, Nielsen B. Recombinant Factor IX. <i>Thromb Haemost</i>. 1997;78(1):261-265.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/9198163/pubmed" id="9198163" target="_blank">9198163</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 93418 Version 170.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
